Want to see PRPH full AI Analyst Report?
PRPH Stock Chart & Stats
$0.06
<$0.01(4.95%)
At close: 4:00 PM EDT
$0.06
<$0.01(4.95%)
Day’s Range― - ―
52-Week Range$0.02 - $6.66
Previous CloseN/A
Volume53.96K
Average Volume (3M)97.64K
Market Cap
$257.44K
Enterprise Value$10.39
Total Cash (Recent Filing)$20.00K
Total Debt (Recent Filing)$9.74M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.12
Shares Outstanding9,493,287
10 Day Avg. Volume69,254
30 Day Avg. Volume97,636
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.88
P/FCF Ratio-0.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Bulls Say, Bears Say
Bulls Say
Liquidity FinancingThe financing provides immediate liquidity to support operations and near-term obligations. While costly and structured, access to new capital may help preserve business continuity during the company’s ongoing operational restructuring.
Asset BaseA substantial asset base gives ProPhase Labs resources that could support restructuring, asset sales, or operational recovery. However, its long-term value depends on management improving returns and converting assets into sustainable earnings and cash flow.
Loss Reduction From 2024The improvement from the unusually large 2024 net loss indicates some reduction in the scale of losses. This is a limited positive, but sustained progress could improve capital preservation if accompanied by revenue stabilization and lower cash usage.
Bears Say
Revenue CollapseThe prolonged revenue collapse shows that the current consumer-health and diagnostics platform is generating only a small fraction of its former scale. This weakens operating leverage, customer reach, and the company’s ability to absorb fixed costs.
Persistent Cash BurnHeavy and worsening cash consumption materially increases dependence on external financing. Without a durable improvement in operating cash flow, liquidity could remain constrained and management may need additional debt, equity, or asset monetization.
Negative Equity And LeverageNegative equity reduces financial flexibility and raises refinancing and solvency risk. Secured convertible borrowing adds repayment and possible dilution exposure, while the weak capital base limits the company’s ability to fund recovery independently.
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $0.02 and its highest was $6.66 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $257.44K.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Nov 05, 2026 which is in 75 days.
How were Prophase Labs’s earnings last quarter?
Prophase Labs released its earnings results on Aug 06, 2026. The company reported -$0.218 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 9,493,287 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Prophase Labs reported an EPS of -$0.218 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.977%.
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prophase Labs
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Technical Analysis
Ownership Overview
37.75%
Insiders
0.23% Mutual Funds
0.89% Other Institutional Investors
61.13% Public Companies and
Individual Investors